Table 2.

Safety and efficacy of aspirin in CKD

StudyStudy TypeParticipantsNEfficacySafety
UK-HARP (25)RCTPredialysis CKD; chronic dialysis; renal transplant448Not analyzed in this studyNo evidence of major bleeding; 3-fold risk of minor bleeding
DOPPS (26)Nested case control study of DOPPS 1–2Randomly selected chronic HD patients28,320No benefit on all-cause mortality; reduced risk of MI and strokeNo increase in GI bleeds
Sciahbasi et al. (27)Retrospective analysisPatients admitted to community hospital with ACS595Patients on chronic low-dose aspirin and statin are less likely to get admitted with STEMINot analyzed
Palmer et al. (28)Meta-analysis9 trials on ACS/PCI; 31 trials on stable or no CAD21,670Little or no effect on all-cause mortality; uncertain effects on cardiovascular mortalityIncrease in major and minor bleeding; uncertain risk of hemorrhagic stroke
  • UK-HARP, First United Kingdom Heart and Renal Protection study; RCT, randomized controlled trial; DOPPS, Dialysis Outcomes and Practice Patterns Study; HD, hemodialysis; MI, myocardial infarction; ; GI, gastrointestinal; ACS, acute coronary syndrome; STEMI, ST elevation myocardial infarction; PCI, percutaneous coronary intervention; CAD, coronary artery disease.